The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease.

Barker, Roger A., Lao-Kaim, Nicholas P., Guzman, Natalie Valle, Athauda, Dilan, Bjartmarz, Hjalmar, Björklund, Anders, Church, Alistair, Cutting, Emma, Daft, Danielle, Dayal, Viswas, Dunnett, Stephen ORCID: https://orcid.org/0000-0003-1826-1578, Evans, Amy, Grealish, Shane, Hannaway, Naomi, He, Xiaoling, Hewitt, Sam, Kefalopoulou, Zinovia, Mahlknecht, Philipp, Martín-Bastida, Antonio, Farrell, Krista, Moore, Sarah, Bulstrode, Harry, Nakornchai, Tagore, Nelander-Wahlestedt, Jenny, Roupé, Linnea, Paul, Gesine, Peall, Kathryn ORCID: https://orcid.org/0000-0003-4749-4944, Rosser, Anne ORCID: https://orcid.org/0000-0002-4716-4753, Roca-Fernández, Adriana, Rowlands, Sophie, McGorrian, Anne-Marie, Scherf, Caroline, Vinh, Ngoc Nga, Roberton, Victoria, Kelly, Claire, Lelos, Mariah ORCID: https://orcid.org/0000-0001-7102-055X, Torres, Eduardo, Shires, Kate, Hills, Rachel, Williams, Debbie, Roussakis, Andreas-Antonios, Sibley, Krista, Tyers, Pamela, Wijeyekoon, Ruwani, Williams-Gray, Caroline, Foltynie, Thomas, Piccini, Paola, Morris, Robert, Lazic, Stanley E., Lindvall, Olle, Parmar, Malin, Widner, Hakan and TransEuro consortium 2025. The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease. Nature Biotechnology 10.1038/s41587-025-02567-2

PDF - Published Version Available under License Creative Commons Attribution. Download (2MB)

Abstract

Transplantation of human fetal ventral mesencephalic tissue in individuals with Parkinson's disease has yielded clinical benefits but also side effects, such as graft-induced dyskinesias. The open-label TransEuro trial ( NCT01898390 ) was designed to determine whether this approach could be further developed into a clinically useful treatment. Owing to poor availability of human fetal ventral mesencephalic tissue, only 11 individuals were grafted at two centers using the same tissue preparation protocol but different implantation devices. No overall clinical effect was seen for the primary endpoint 3 years after grafting. No major graft-induced dyskinesias were seen, but we observed differences in outcome related to transplant device and/or site. Mean dopamine uptake improved at 18 months in seven individuals according to [ F]fluorodopa positron emission tomography imaging but was restored to near-normal levels in only one individual. Our findings highlight the need for a stem cell source of dopamine neurons for potential Parkinson's disease cell therapy and provide critical insights into how such clinical studies should be approached. [Abstract copyright: © 2025. The Author(s).]

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Medicine Schools > Biosciences
Publisher:	Nature Research
ISSN:	1087-0156
Date of First Compliant Deposit:	3 June 2025
Date of Acceptance:	17 January 2025
Last Modified:	03 Jun 2025 10:36
URI:	https://orca.cardiff.ac.uk/id/eprint/178705

Actions (repository staff only)

Edit Item